

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 8-K/A

PROVECTUS PHARMACEUTICALS INC

Form 8-K/A

November 12, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K/A

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 27, 2004

PROVECTUS PHARMACEUTICALS, INC.  
(Exact Name of Registrant as Specified in Charter)

|   |                             |  |
|---|-----------------------------|--|
| Nevada  | 0-9410                      | 90-0031917                                 |
| (State or Other Jurisdiction of<br>Incorporation or Organization) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification Number) |

7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: 865/769-4011

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.1. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) (UIR:FRK2541) announced today, October 27, 2004, that one of the largest national distributors of pharmaceutical products has accepted delivery of the company's Pure-ific

## Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 8-K/A

antibacterial hand spray for sale in 504 stores in the western region of the United States.

"We are particularly happy to get this campaign started right now, at the onset of cold and flu season, and we expect to build upon this beginning and extend sales into other regions of the country," said Pure-ific President Timothy C. Scott, Ph. D. "This first shipment of product is destined for sales in the states of California, Utah, Arizona, and Washington."

Pure-ific, which comes in a 1-ounce can, immediately kills up to 99.9 percent of germs on skin and prevents re-growth for up to six hours. Packaged as a quick-drying spray, Pure-ific is useful for mothers, travelers, and anyone else concerned about the spread of germs. Unlike gel sanitizers, Pure-ific Antibacterial Hand Spray leaves no sticky residue and is appropriate both for hands and for hard surfaces, such as toilet seats.

Provectus Pharmaceuticals Inc. plans to license and sell products in three sectors of the health-care industry: 1) prescription medications and treatments, 2) medical devices, and 3) over-the-counter (OTC) pharmaceuticals, such as Pure-ific. Prescription drug products and devices address several forms of difficult-to-treat cancers as well as diseases of the skin. OTC products address complementary markets, primarily those involving skin care and comfort.

The company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A Knoxville, TN 37931; telephone: 865/769-4011. For more information, contact the company at [info@pvct.com](mailto:info@pvct.com) or visit the corporate Web site: [www.pvct.com](http://www.pvct.com).

### Forward-Looking Statements

This information and others statements issued or made from time to time by the company or its representatives contain statements that may constitute forward-looking statements. Those statements include statements regarding the intent, belief or current expectations of the company and members of its management teams as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.

---

Corporate Contact: Provectus Pharmaceuticals, Craig Dees, CEO (865) 769-4011  
Media Contacts: Emily Carlton or George Pappas, HKA, Inc., 714 426-0444 (PDT),  
[Emily@hkamarcom.com](mailto:Emily@hkamarcom.com)

Source: Provectus Pharmaceuticals Inc.

### Terms of the Agreement

The Supply Agreement is a nonexclusive agreement whereby Provectus agrees to sell products to AmerisourceBergen as an authorized distributor of record. The Agreement continues until June 1, 2005 and thereafter automatically renews for subsequent terms of one year.

### Item 9.01 Financial Statements and Exhibits

#### (a) Exhibits

99.1 Supply Agreement between AmerisourceBergen Drug Corporation and Provectus Pharmaceuticals, Inc. dated June 1, 2004.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Provectus Pharmaceuticals, Inc.

Dated: November 10, 2004

By:/s/ H. Craig Dees

-----  
H. Craig Dees  
Chief Executive Officer